教育/科研工作经历 

科研成果

主要从事纳米药物递送及肿瘤微环境调控研究。以第一作者（含共同）在相关领域期刊发表SCI论文9篇。

科研方向

肿瘤免疫治疗、药物递送

代表性研究论文

[1] Ye Liu#, Qingyu Zong#, Yalan Tu, XingzuZhang, Qiaoling Tan, Ihsan Ullah, and Youyong Yuan*, A Tumor Heterogeneity-Independent Antigen-Responsive Nanocarrier Enabled by Bioorthogonal Pre-Targeting and Click-Activated Self-Immolative Polymer. Biomaterials, 2025, 319, 123200.

[2] Maolin Jiang#，Ye Liu#， Kewei Wang，Yansong Dong，Xiangyu Hu，Youyong Yuan*，Mutually reinforced activatable NIR fluorescence/MR bimodal imaging enabled by tumor-specific biomarker amplification. Cell Biomaterials, 2025, 100044.

[3] Ye Liu#, Haiyang Wang#, Mengchao Ding,Wang Yao, Kewei Wang, Ihsan Ullah, Emil Bulatov, and Youyong Yuan*, Ultrasound-Activated PROTAC Prodrugs Overcome Immunosuppression to Actuate Efficient Deep-Tissue Sono-Immunotherapy in Orthotopic Pancreatic Tumor Mouse Models, Nano Lett., 2024, 24, 8741–8751.

[4] Yansong Dong#, Ye Liu#, Yalan Tu,Youyong Yuan* and Jun Wang*, AIEgens Cross-Linked Iron Oxide Nanoparticles Synchronously Amplify Bimodal Imaging Signals in Situ by Tumor Acidity-Mediated Click Reaction. Angew. Chem. Int. Ed., 2023, 62, e202310975.

[5] Ye Liu#, Maolin Jiang#, Zhongyi Zhao,Nianhua Wang, Kewei Wang, and Youyong Yuan*, Cyclic Amplification ofIntracellular ROS Boosts Enzymatic Prodrug Activation for Enhanced Chemo-Immunotherapy, Acta Biomaterialia, 2023, 166, 567-580.

[6] Maolin Jiang#, Ye Liu#, YansongDong, Kewei Wang, and Youyong Yuan*, Bioorthogonal Chemistry and Illumination Controlled Programmed Size-Changeable Nanomedicine for Synergistic Photodynamicand Hypoxia-Activated Therapy, Biomaterials, 2022, 284, 121480.

[7] Ye Liu#, Maolin Jiang#, Yalan Tu, Kewei Wang, Qingyu Zong, Youyong Yuan∗. Time-Programmed Activation of Dual Polyprodrugs for Synergistic Cascade Oxidation-Chemotherapy. Biomaterials, 2021, 278: 121136.

[8] Zhaoming Guo#, Ye Liu#, Xiao Cheng, Dong Wang,Shubin Guo, Mingli Jia, Kun Ma, Changhao Cui, Li Wang, Hao Zhou. Versatile Biomimetic Cantharidin-Tellurium Nanoparticles Enhance Photothermal Therapy by Inhibiting the Heat Shock Response for Combined Tumor Therapy. Acta Biomaterialia,2020, 110, 208-220.

[9] Zhaoming Guo#, Ye Liu#, Hao Zhou, Kun Zheng,Dong Wang, Mingli Jia, Pengcheng Xu, Kun Ma, Changhao Cui. CD47-Targeted Bismuth Selenide Nanoparticles Actualize Improved Photothermal Therapy by Increasing Macrophage Phagocytosis of Cancer Cells. Colloids and Surfaces B:Biointerfaces, 2019, 184, 110546.